Mizuho Maintains Outperform on LifeMD, Lowers Price Target to $6

Benzinga · 18h ago
Mizuho analyst Steven Valiquette maintains LifeMD (NASDAQ:LFMD) with a Outperform and lowers the price target from $7 to $6.